Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Sitravatinib/Tislelizumab Combo Induces Antitumor Activity in PD-L1+ Advanced NSCLC
Sitravatinib in combination with tislelizumab demonstrated a confirmed investigator-assessed overall response rate of 30.4% in patients with PD-L1–positive, treatment-naïve, locally advanced or metastatic squamous non–small cell lung cancer.
GDC-6036 Monotherapy Elicits Promising Responses in KRAS G12C–Mutant NSCLC
GDC-6036, a novel KRAS G12C inhibitor, produced encouraging antitumor activity with a manageable safety profile as a single agent in previously treated patients with KRAS G12C–mutated NSCLC, according to data from a phase 1a trial.
Subtyping MET Exon 14 Skipping Mutations Provides Insight Into Distinct Microenvironments in NSCLC
August 7th 2022Four distinct subgroups, each associated with distinctive signaling pathways, microenvironments, and clinical-pathologic futures, were discovered in a population of patients with MET exon 14 skipping non–small cell lung cancer.
Consolidation Sugemalimab Provides Sustained PFS Benefit in Unresectable Stage III NSCLC
August 7th 2022Sugemalimab appeared to be safe and effective when used as consolidation therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) who did not have disease progression following concurrent chemoradiation or sequential chemoradiation.
Durvalumab/Tremelimumab Combo Provides OS Benefit in First-Line Metastatic NSCLC
August 6th 2022The combination use of first-line durvalumab plus tremelimumab for the treatment of patients with metastatic non–small cell lung cancer improved overall survival compared with standard-of-care chemotherapy.
Larotrectinib Demonstrates Favorable Long-Term Responses in NTRK Fusion–Positive Lung Cancer
August 6th 2022Larotrectinib continued to elicit durable responses and a low toxicity profile in patients with NTRK fusion–positive lung cancer, according to long-term follow-up data from the phase 2 NAVIGATE trial and phase 1 LOXO-TRK-14001 trial.
Ociperlimab Plus Tislelizumab Demonstrates Antitumor Activity in PD-L1+ NSCLC
Ociperlimab, an anti-TIGIT monoclonal antibody, plus the anti–PD-L1 monoclonal antibody tislelizumab induced promising efficacy in adults with treatment-naïve, metastatic, PD-L1–positive non–small cell lung cancer, according to data from the dose-expansion cohort of the AdvanTIG-105 trial.
Tremelimumab/Durvalumab Plus Chemotherapy Improves OS in PD-L1–Negative NSCLC
The addition of tremelimumab to durvalumab and chemotherapy improved clinical benefit and survival benefit vs. chemotherapy alone in patients with PD-L1–negative metastatic non–small cell lung cancer.
Neoadjuvant Adagrasib Alone or With Nivolumab May Improve pCR Rates in NSCLC
August 6th 2022Neoadjuvant adagrasib as monotherapy or in combination with nivolumab may elicit improved pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer, according to the rationale for the phase 2 Neo-KAN study.
Osimertinib/Savolitinib Combo Looks to Overcome Acquired Resistance in EGFR-Mutant NSCLC
August 5th 2022Acquired resistance because of genetic alterations in the MET receptor has limited the efficacy of the EGFR inhibitor osimertinib in patients with non–small cell lung cancer. Investigators have sought to circumvent this barrier through targeting MET protein activity with the addition of the novel MET TKI, savolitinib.
Understanding the Role of pCR in Early-Stage TNBC Opens Doors for Tailored Treatment
As ongoing research efforts are shifting further into personalized care, Hope S. Rugo, MD, FASCO discusses how pathologic complete response and the predictive value of residual cancer burden scoring are becoming a pivotal end point for the changing triple-negative breast cancer landscape.
How Low Can We Go? Metastatic Breast Cancer Enters a New Era of HER2 Classification
July 30th 2022Erika P. Hamilton, MD, shares how multidisciplinary collaboration between pathologist and breast oncologists is key to staying abreast of not only the classification-actionable HER2 mutations in metastatic breast cancer but also the evolving definition of expression.
Glutaminase Inhibition Represents Novel Treatment Strategy in NFE2L2- and KEAP1-Mutated NSCLC
Jonathan Wesley Riess, MD, MS, discusses a phase 1 trial examining the combination of sapanisertib and telaglenastat, and explains why glutaminase inhibition is being investigated as a novel way to treat select patients with non–small cell lung cancer.
EGFR TKI–Based Combos Could Lead to More Tailored First-Line Treatment Options in EGFR-Mutated NSCLC
Leveraging EGFR TKIs as a backbone for combination therapies will be pivotal for expanding treatment options and delivering more personalized therapies in the first-line setting for patients with non–small cell lung cancer harboring EGFR mutations.
Novel Biomarker Testing Could Enhance Immunotherapy Treatment Decisions in NSCLC
PD-L1 and tumor mutational burden are established biomarkers for leveraging immunotherapy in non–small cell lung cancer; however, their use may not be appropriate in determining treatment decisions for all patients.
